WiCON Publishes the China Pharmaceutical Guide 2021 (16th Edition)
WiCON International Group LLC, the publisher of well-known WiCON | Pharma China (www.pharmachinaonline.com), announced that its China Pharmaceutical Guide 2021 (16th Edition) is now officially published. Now in its 16th edition, China Pharmaceutical Guide 2021 is thoroughly updated with the latest ample data from many reputable sources, abundant analysis by leading industry experts, new regulations and more case studies. - September 21, 2021
WiCON Publishes the China Pharmaceutical Guide 2020 - Stabilizing Growth Amid Deepening Reform
WiCON International Group LLC, the publisher of well-known WiCON | Pharma China (www.pharmachinaonline.com), announced that its China Pharmaceutical Guide 2020 (15th Edition) is now published. The publication reports stabilizing Chinese pharma growth amid deepening healthcare and drug regulatory reform. - September 20, 2020
WiCON Publishes the China Pharmaceutical Guide 2019 (14th Edition)
Chinese Pharma Growth Stabilizes amid Deepening Healthcare and Drug Regulatory Reform. - September 09, 2019
WiCON to Hold Pharma China Annual Forum 2019 in Shanghai on April 9
WiCON International Group LLC, the publisher of well-known WiCON | Pharma China (www.pharmachinaonline.com), announced that it will host the “Pharma China Annual Forum 2019” in Shanghai on April 9. Sponsored by RDPAC and Kantar Health, the well-acclaimed English language event has been... - January 30, 2019
WiCON Publishes the China Pharmaceutical Guide 2018 (13th Edition) - Chinese Pharma Growth Stabilizes Amid Deepening Healthcare and Drug Regulatory Reform
WiCON International Group LLC announced that it has officially published its China Pharmaceutical Guide 2018 (13th Edition). According to the publication, the size of China’s pharmaceutical market is estimated to be around CNY 1.9 trillion at the retail price level in 2017. Growth of the market fell slightly further to 7.6% last year (vs. 8.2% in 2016), but there are signs of stabilization in 2018. - September 13, 2018
Chinese Pharma Growth Stabilizes Amid Deepening Healthcare and Drug Regulatory Reform
WiCON International Group LLC, the publisher of well-known WiCON | Pharma China (www.pharmachinaonline.com), announced that it will officially publish its China Pharmaceutical Guide 2018 (13th Edition) in August 2018. According to the publication, quoting latest data from SMEI, the size of... - May 10, 2018
China Overhauls Drug, Medical Insurance and Healthcare Regulation in Latest Government Reshuffle
One of the primary aims of the reorganization of central government is to overhaul China’s future healthcare and pharmaceutical regulation substantially, said WiCON|Pharma China (www.pharmachinaonline.com), which has summarized most important government organizational changes which will take place as proposed by the reform plan. - March 16, 2018
China Solicits Comments on Imlementation Rules for Confidentiality of Drug Registration Information
The CFDA released on December 1 a draft document, Implementation Rules for Confidentiality Management of Drug Evaluation and Approval Information, for public comments, according to WiCON|Pharma China (www.pharmachinaonline.com), the most trusted English media and business intelligence service covering the Chinese pharmaceutical marketplace, quoting information from the CFDA. - December 06, 2017
WiCON|Pharma China: Chinese Drug Market Growth Projected to Slow But Stabilize in the Next Five Years
The Chinese drug market growth is expected to fall further to 7.6% valued at CNY 1,611.8 billion (at retail price level) in 2017 as a result of tender price pressure, eliminated hospital drug sales margin and stringent government cost containment measures, according to WiCON|Pharma China... - November 10, 2017
WiCON Publishes the China Pharmaceutical Guide 2017 (12th Edition)
WiCON International Group LLC, the publisher of well-known WiCON | Pharma China (www.pharmachinaonline.com), announced the official publication of its China Pharmaceutical Guide 2017 (12th Edition). The publication, an indispensable reference for MNC pharma executives with China responsibilities for more than a decade, continues to play an instrumental role in helping executives understand, navigate, manage and lead their pharmaceutical businesses in China. - September 01, 2017
Chinese Pharma Maintains Decent Growth and Prospects Amid Deepened Reform
WiCON Announces Upcoming Publication of China Pharmaceutical Guide 2017 (12th Edition) - The Chinese pharmaceutical market rose slower in 2016 at only 8.3% to CNY 1,497.5 billion at retail price level, compared with 11.0% in 2015, according to the China Pharmaceutical Guide 2017 (12th Edition), which is to be published in August 2017, and WiCON | Pharma China (www.pharmachinaonline.com) quoting official SMEI data. - April 21, 2017
Chinese Pharma Rebounded to Double-Digit Growth in H1/2016 Despite Challenges
Core business revenues of the Chinese pharmaceutical industry grew 10.14% to CNY 1,363,565 million in the first half of 2016, according to the newly published China Pharmaceutical Guide 2016 (11th Edition) and WiCON | Pharma China (www.pharmachinaonline.com) quoting the official statistics. - September 06, 2016
Chinese Pharma Market Prospects Remain Robust as New Drivers Emerge
Despite slowing Chinese pharma market growth to 7.6% in 2015, it remains a high growth spot with numerous emerging opportunity areas, according to the China Pharmaceutical Guide 2016 (11th Edition). Hot off the press, the China Pharmaceutical Guide 2016, an indispensable reference for MNC executives with China responsibilities for over a decade, aims to help proactive HQ and local executives feel the pulse of Chinese healthcare and stay in the driver seat of their business in the country. - August 09, 2016
WiCON and PharmaGuys Launch Pharma China Training Institute
Pharma China Training Institute (PCTI, www.pharmachinatraining.com) was created by WiCON International Group LLC, the publisher of Pharma China, and PharmaGuys to meet the growing needs of healthcare/pharma MNCs in China for internationally-advanced professional training, coaching and other service solutions. - July 21, 2015
Chinese Pharma Growth Slowed Further in 2014 But Still Impressive
In general the Chinese pharmaceutical sector saw slower but still double-digit growth in 2014 despite a host of challenges stemmed from slowing Chinese economy, regulatory shakeups, cost containment measures and price cuts, as well as healthcare reform turbulences. The Chinese drug market (at... - January 25, 2015
Chinese Pharma Growth Remains Impressive in 2013-2014 Despite Challenges and Crackdowns
By large, the Chinese pharmaceutical sector still saw double-digit growth in 2013 and the first half of 2014 despite a host of challenges stemmed from slowing Chinese economy, regulatory shakeups, cost containment measures and price cuts, as well as healthcare reform turbulences, according to the... - July 25, 2014
Chinese Pharma Performance Slows Further in 2013 Amid Government Crackdowns
The overall trend of Chinese pharma this year shows continued decline of profitability despite sustained relatively high output value and revenue growth. Both hospital drug sales and pharmaceutical retail sales growth are slowing, while western medicine foreign trade remained to grow at a low rate, according to China Pharmaceutical Guide 2013 (8th Edition) from WiCON International Group LLC, the publisher of Pharma China. - November 08, 2013
Chinese Pharma Growth Slows, But with Unchanged Long Term Positive View
The Chinese pharmaceutical industry and market in 2012/2013 was characterized by slowing growth, falling profitability, mixed regulatory developments, renewed price cutting initiatives, superficial healthcare reform progress driven primarily by cost containment measures, fallen healthcare quality, according to China Pharmaceutical Guide 2013 (8th Edition), which was officially published today by WiCON International Group LLC, the publisher of Pharma China. - July 08, 2013
Chinese Pharma Growth Expected to Slow Amid Reform Turbulences and Intensified Cost Containment
Although there are growing concerns about China’s economy and uncertainties about the country’s healthcare reforms, the Chinese pharmaceutical industry maintained healthy growth in 2011 and the first half of 2012 as well as a generally positive outlook, according to China Pharmaceutical... - July 06, 2012
Chinese Pharma Prospects Clouded by Increased Short Term Risks Despite Another High Performance Year in 2010
Notwithstanding the challenges, the Chinese pharmaceutical industry and market managed to post high growth again in 2010, according to China Pharmaceutical Guide 2011 (6th Edition), which was officially inaugurated today by WiCON International Group LLC, the publisher of Pharma China. Nonetheless, increased short term risk factors and uncertainties recently are clouding the future prospects of Chinese pharma for MNC companies. - June 29, 2011
Chinese Pharma Powers on Despite Global Economic Slowdown
According to China Pharmaceutical Guide 2010 (5th Edition), which was officially released in July 2010 by WiCON International Group LLC (publisher of Pharma China), the Chinese pharmaceutical sector maintained its high growth trend in 2009 despite the global financial crisis and economic slowdown. - July 09, 2010
Is the Chinese Pharmaceutical Market Finally Ripe for MNC Pharma Companies?
According to China Pharmaceutical Guide 2009 (4th Edition), the latest report from Wicon International Group LLC (publisher of Pharma China), the size of the Chinese drug market (including all Western and traditional Chinese medicine drug products and biopharmaceuticals) at retail price level grew... - June 11, 2009
Fundamentals of Chinese Pharma Industry Remain Strong Despite Anticipated Slower Growth in 2H/2008
While the Chinese pharmaceutical industry reported highly positive performance in the first half of 2008, WiCON International Group, the publisher of Pharma China and China Pharmaceutical Guide, expects the industry’s growth to slow down somewhat in the second half of 2008. Most... - September 12, 2008
Chinese Drug Market Jumped 19% in 2007 to US$50 Bln - WiCON Launches China Pharmaceutical Guide 2008 (3rd Edition)
WiCON International Group, the publisher of Pharma China, announced the official publication of its China Pharmaceutical Guide 2008 (3rd Edition). According to latest estimates by WiCON in this annually-updated Guide, the size of the Chinese drug market (including all Western and traditional... - June 10, 2008